Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
Background Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate the synergistic effect of clarithromycin (CAM) with cisplatin to inhibit ovarian carcinoma cells growth in vitro and in vivo. Results We performed CCK-8 assay to detect apoptosis rates in response to CAM alone or in combination with cisplatin, which were further confirmed by Annexin V and PI staining methods and western blotting. Mechanistically, CAM could reduce endogenous antioxidant enzyme expression and increase the levels of reactive oxygen species (ROS) to augment the cytotoxic effect of cisplatin. Meanwhile, a tumor xenograft model in athymic BALB/c-nude mice demonstrated that CAM combined with cisplatin resulted in reduced tumor growth and weight compared with cisplatin alone. Conclusion Collectively, our results indicate that CAM works synergistically with cisplatin to inhibit ovarian cancer cell growth, which may be manipulated by a ROS-mediated mechanism that enhances cisplatin therapy, and offers a novel strategy for overcoming cisplatin therapy resistance..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of ovarian research - 12(2019), 1 vom: 08. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Bo [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Cisplatin-resistance |
|---|
| Anmerkungen: |
© The Author(s). 2019 |
|---|
| doi: |
10.1186/s13048-019-0570-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR029672694 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR029672694 | ||
| 003 | DE-627 | ||
| 005 | 20230519172636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13048-019-0570-9 |2 doi | |
| 035 | |a (DE-627)SPR029672694 | ||
| 035 | |a (SPR)s13048-019-0570-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Bo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2019 | ||
| 520 | |a Background Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate the synergistic effect of clarithromycin (CAM) with cisplatin to inhibit ovarian carcinoma cells growth in vitro and in vivo. Results We performed CCK-8 assay to detect apoptosis rates in response to CAM alone or in combination with cisplatin, which were further confirmed by Annexin V and PI staining methods and western blotting. Mechanistically, CAM could reduce endogenous antioxidant enzyme expression and increase the levels of reactive oxygen species (ROS) to augment the cytotoxic effect of cisplatin. Meanwhile, a tumor xenograft model in athymic BALB/c-nude mice demonstrated that CAM combined with cisplatin resulted in reduced tumor growth and weight compared with cisplatin alone. Conclusion Collectively, our results indicate that CAM works synergistically with cisplatin to inhibit ovarian cancer cell growth, which may be manipulated by a ROS-mediated mechanism that enhances cisplatin therapy, and offers a novel strategy for overcoming cisplatin therapy resistance. | ||
| 650 | 4 | |a Ovarian cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Clarithromycin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cisplatin-resistance |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Combination therapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Xia, Meng |4 aut | |
| 700 | 1 | |a Wang, Bin |4 aut | |
| 700 | 1 | |a Thapa, Niresh |4 aut | |
| 700 | 1 | |a Gan, Lijuan |4 aut | |
| 700 | 1 | |a Sun, Chaoyang |4 aut | |
| 700 | 1 | |a Guo, Ensong |4 aut | |
| 700 | 1 | |a Huang, Jia |4 aut | |
| 700 | 1 | |a Lu, Yulan |4 aut | |
| 700 | 1 | |a Cai, Hongbin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ovarian research |d London : BioMed Central, 2008 |g 12(2019), 1 vom: 08. Nov. |w (DE-627)SPR029663997 |w (DE-600)2455679-8 |x 1757-2215 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2019 |g number:1 |g day:08 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13048-019-0570-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2019 |e 1 |b 08 |c 11 | ||